Overview

The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn about the role of noradrenergic system in the non-motor symptoms of Parkinson's disease. In particular, researchers hope to better understand what role the noradrenergic system may play in the regulation of blood pressure, cognition and mood symptoms in patients with Parkinson's disease. With this information, future research may explore treatments that target the noradrenergic system in order to better treat the non-motor symptoms of Parkinson's disease. The experimental drug used in some of the study assessments, yohimbine hydrochloride, is not being tested as a potential treatment for Parkinson's disease. Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones and neurotransmitters the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning.
Phase:
Early Phase 1
Details
Lead Sponsor:
Nathaniel M. Robbins
Treatments:
Yohimbine